BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 88 filers reported holding BRIDGEBIO PHARMA INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15 | +66.7% | 550 | 0.0% | 0.00% | – |
| Q2 2023 | $9 | -93.5% | 550 | -93.4% | 0.00% | -100.0% |
| Q1 2023 | $138 | +165.4% | 8,297 | +22.5% | 0.00% | – |
| Q4 2022 | $52 | -99.9% | 6,775 | -23.1% | 0.00% | -100.0% |
| Q3 2022 | $88,000 | +1660.0% | 8,808 | +1501.5% | 0.00% | – |
| Q2 2022 | $5,000 | +25.0% | 550 | +28.2% | 0.00% | – |
| Q1 2022 | $4,000 | -42.9% | 429 | 0.0% | 0.00% | – |
| Q4 2021 | $7,000 | -70.8% | 429 | -16.4% | 0.00% | – |
| Q3 2021 | $24,000 | +33.3% | 513 | +73.9% | 0.00% | – |
| Q2 2021 | $18,000 | 0.0% | 295 | 0.0% | 0.00% | – |
| Q1 2021 | $18,000 | +12.5% | 295 | +27.7% | 0.00% | – |
| Q4 2020 | $16,000 | -38.5% | 231 | -66.9% | 0.00% | – |
| Q3 2020 | $26,000 | +30.0% | 697 | 0.0% | 0.00% | – |
| Q2 2020 | $20,000 | 0.0% | 697 | 0.0% | 0.00% | – |
| Q1 2020 | $20,000 | -16.7% | 697 | 0.0% | 0.00% | – |
| Q4 2019 | $24,000 | – | 697 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |